|
e-Therapeutics - Media Relations
e-Therapeutics is a publicly listed (LSE:ETX), drug discovery and development company based in Newcastle, UK. The Company is leading the way in the emerging market of network pharmacology to discover multi-targeted drug candidates in areas of high unmet clinical need. The Company’s systematic approach optimises the probability of identifying drug candidates with desirable efficacy and minimal side effects.
e-Therapeutics has three lead drug candidates, all at phase II, and include; Dexanabinol (ETS2101), a cancer candidate for targeting glioblastoma; Clostriban (ETX1153c), for the treatment of Clostridium difficile; and Viotra (ETS6103) to treat depression.
Objectives
- To prepare the Company before the financing announcement was made.
- To generate media coverage on e-Therapeutics’ financing news in the trade and business media.
Our Approach
- Identified all top tier media (investment and trade) in Europe to target for media interviews and outreach. We also established any connections or links the Company had with these media already.
- Provided strategic counsel and identified key facts and themes both within the UK biotech industry and about e-Therapeutics to maximise the impact of media outreach. Copywrote the announcement and materials. College Hill drew attention to e-Therapeutics’ achievement in securing a substantial fundraising relative to market capitalisation in the current marketplace and at a premium to the share price.
- Proactive medial relations and initiated the beginnings of a media network with top tier business and trade journalists through one-to-one interviews with the Company’s CEO.
Results
- Secured a substantial amount of coverage for e-Therapeutics throughout the top tier business and trade media including The Times, The Daily Mail, ThomsonReuters, Dow Jones, Investors Chronicle, Growth Company Investor, EP Vantage, BioCentury, Scrip, BioWorld International, MedNous, In Vivo and Biotech Finances.
- 1:1 media interviews secured with the Financial Times, Dow Jones Newswire, Growth Company Investor, Proactive Investor, EP Vantage, In Vivo, MedNous, Biotech Finances and The Newcastle Journal.
- Widespread awareness raised with top tier journalists who had not spoken to e-Therapeutics before and/or were previously unaware of the Company.
Client Endorsement
Malcolm Young, CEO, e-Therapeutics, “We were so impressed with the strategic advice that we received from College Hill consultants concerning our financing announcement and the media coverage achieved that we have decided to now retain College Hill to drive our financial and corporate PR.”
April 2011
To discuss our capability in this area please contact:
Melanie Toyne Sewell, Head of Financial PR, Life Sciences
+44 (0)20 7457 2020
melanie.toynesewell[at]collegehill.com
|
Quick links
